Literature DB >> 12804056

Intraocular adenosine levels in normal and ocular-hypertensive patients.

Bradley S Daines1, Alexander R Kent, Melissa S McAleer, Craig E Crosson.   

Abstract

PURPOSE: Adenosine receptors modulate several ocular responses; however, our understanding of factors that influence ocular extracellular adenosine levels is limited. The objective of this study was to evaluate how changes in intraocular pressure (IOP) influence endogenous levels of the purines adenosine and inosine, in the aqueous humor of normal and ocular-hypertensive patients. PATIENTS AND METHODS: Informed consent was obtained from 51 individuals undergoing cataract extraction or glaucoma surgical procedures. IOP was measured immediately prior to surgery. At the start of the surgical procedure, an aqueous sample of 75-100 microL was obtained. Purine levels were determined by reverse-phase HPLC.
RESULTS: In normotensive individuals, mean aqueous adenosine and inosine levels were 5.2 +/- 1.1 and 19.4 +/- 2.2 ng/100 microL, respectively. No significant correlation between IOP and purine concentration was measured in this group. In ocular hypertensive individuals, the mean aqueous adenosine and inosine concentration was significantly elevated when compared to normotensive individuals. In the ocular hypertensive individual, this elevation in adenosine level was significantly correlated with IOP (r(2) = 0.42).
CONCLUSIONS: These results demonstrate that in ocular hypertensive individuals, aqueous adenosine concentration is correlated with IOP. As the activation of adenosine receptors can modulate IOP and retinal blood flow, adenosine release during periods of ocular hypertension may play an important role in the physiological responses to elevated IOP.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12804056     DOI: 10.1089/108076803321637645

Source DB:  PubMed          Journal:  J Ocul Pharmacol Ther        ISSN: 1080-7683            Impact factor:   2.671


  12 in total

1.  Advances in glaucoma treatment and management: outflow drugs.

Authors:  Paul L Kaufman; Carol A Rasmussen
Journal:  Invest Ophthalmol Vis Sci       Date:  2012-05-04       Impact factor: 4.799

Review 2.  Ocular Purine Receptors as Drug Targets in the Eye.

Authors:  Kenneth A Jacobson; Mortimer M Civan
Journal:  J Ocul Pharmacol Ther       Date:  2016-08-30       Impact factor: 2.671

3.  The cross-species A3 adenosine-receptor antagonist MRS 1292 inhibits adenosine-triggered human nonpigmented ciliary epithelial cell fluid release and reduces mouse intraocular pressure.

Authors:  Hui Yang; Marcel Y Avila; Kim Peterson-Yantorno; Miguel Coca-Prados; Richard A Stone; Kenneth A Jacobson; Mortimer M Civan
Journal:  Curr Eye Res       Date:  2005-09       Impact factor: 2.424

4.  [Functional significance of adenosine receptors in the eye and their dysregulation in pseudoexfoliation syndrome].

Authors:  U Schlötzer-Schrehardt; M Zenkel; C Hofmann-Rummelt; F E Kruse; G O Naumann
Journal:  Ophthalmologe       Date:  2005-11       Impact factor: 1.059

5.  In vitro effect of adenosine on the mRNA expression of Kir 2.1 and Kir 4.1 channels in rat retinal Müller cells at elevated hydrostatic pressure.

Authors:  Jun Yu; Chongda Chen; Jun Wang; Yu Cheng; Qirong Wu; Yisheng Zhong; Xi Shen
Journal:  Exp Ther Med       Date:  2012-01-19       Impact factor: 2.447

6.  Effect of A(2A) receptor antagonist (SCH 442416) on the mRNA expression of glutamate aspartate transporter and glutamine synthetase in rat retinal Müller cells under hypoxic conditions in vitro.

Authors:  Jun Yu; Xin Huang; Qirong Wu; Jun Wang; Xiaoyan Yu; Peiquan Zhao
Journal:  Exp Ther Med       Date:  2012-02-13       Impact factor: 2.447

Review 7.  Targeting Schlemm's Canal in the Medical Therapy of Glaucoma: Current and Future Considerations.

Authors:  Vanessa Andrés-Guerrero; Julián García-Feijoo; Anastasios Georgios Konstas
Journal:  Adv Ther       Date:  2017-03-27       Impact factor: 3.845

8.  A Randomized Phase 1 Dose Escalation Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Trabodenoson in Healthy Adult Volunteers.

Authors:  Alan Laties; Cadmus C Rich; Randall Stoltz; Vernon Humbert; Chaim Brickman; William McVicar; Rudolf A Baumgartner
Journal:  J Ocul Pharmacol Ther       Date:  2016-04-05       Impact factor: 2.671

9.  Elevated Pressure Changes the Purinergic System of Microglial Cells.

Authors:  Ana C Rodrigues-Neves; Inês D Aires; Joana Vindeirinho; Raquel Boia; Maria H Madeira; Francisco Q Gonçalves; Rodrigo A Cunha; Paulo F Santos; António F Ambrósio; Ana R Santiago
Journal:  Front Pharmacol       Date:  2018-01-24       Impact factor: 5.810

10.  A Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of 2 and 4 Weeks of Twice-Daily Ocular Trabodenoson in Adults with Ocular Hypertension or Primary Open-Angle Glaucoma.

Authors:  Jonathan S Myers; Kenneth N Sall; Harvey DuBiner; Natanya Slomowitz; William McVicar; Cadmus C Rich; Rudolf A Baumgartner
Journal:  J Ocul Pharmacol Ther       Date:  2016-03-22       Impact factor: 2.671

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.